Metabolic disorders of fatty acids and fatty acid amides associated with human gastric cancer morbidity

Chinese Medical Journal

Volumn 125, Issue 5, 2012, Pages 757-763

  Song, Hu ^a   Peng, Jun Sheng ^b   Yao, Dong Sheng ^c   Liu, Da Ling ^c   Yang, Zu Li ^b   Du, Yan Ping ^b   Xiang, Jun ^b  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c JINAN UNIVERSITY   (China)

Author keywords

Amides; Fatty acids; Gastric cancer; Metabolic disorders

Indexed keywords

AMIDE; FATTY ACID; FATTY ACID AMIDE; OLEAMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; FEMALE; GASTROINTESTINAL MUCOSA; HUMAN; HUMAN TISSUE; MALE; MASS FRAGMENTOGRAPHY; MORBIDITY; STOMACH CANCER;

AMIDES; FATTY ACIDS; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; METABOLIC DISEASES; STOMACH NEOPLASMS;

EID: 84863360942     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.05.007     Document Type: Article

References (43)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12: 354-362.
3. Kikuchi R, Abe Y, Iijima K, Koike T, Ara N, Uno K, et al. Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with high-risk of early gastric cancer. Tohoku J Exp Med 2011; 223: 35-44.
4. Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol 2003; 98: 735-739.
5. Mal M, Koh PK, Cheah PY, Chan EC. Development and validation of a gas chromatography/mass spectrometry method for the metabolic profiling of human colon tissue. Rapid Commun Mass Spectrom 2009; 23: 487-494.
6. Duplus E, Forest C. Is there a single mechanism for fatty acid regulation of gene transcription? Biochem Pharmacol 2002; 64: 893-901.
7. Li D. Omega-3 fatty acids and non-communicable diseases. Chin Med J 2003; 116: 453-458.
8. Stiban J, Tidhar R, Futerman AH. Ceramide synthases: roles in cell physiology and signaling. Adv Exp Med Biol 2010; 688: 60-71.
9. Mendelson WB, Basile AS. The hypnotic actions of the fatty acid amide, oleamide. Neuropsychopharmacology 2001; 25: S36-S39.
10. Arafat ES, Trimble JW, Andersen RN, Dass C, Desiderio DM. Identification of fatty acid amides in human plasma. Life Sci 1989; 45: 1679-1687.
11. Boger DL, Henriksen SJ, Cravatt BF. Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules. Curr Pharm Des 1998; 4: 303-314.
12. Boger DL, Patterson JE, Guan X, Cravatt BF, Lerner RA, Gilula NB. Chemical requirements for inhibition of gap junction communication by the biologically active lipid oleamide. Proc Natl Acad Sci U S A 1998; 95: 4810-4815.
13. Cravatt BF, Prospero-Garcia O, Siuzdak G, Gilula NB, Henriksen SJ, Boger DL, et al. Chemical characterization of a family of brain lipids that induce sleep. Science 1995; 268: 1506-1509.
14. Yang JY, Abe K, Xu NJ, Matsuki N, Wu CF. Oleamide attenuates apoptotic death in cultured rat cerebellar granule neurons. Neurosci Lett 2002; 328: 165-169.
15. Ockner RK, Kaikaus RM, Bass NM. Fatty-acid metabolism and the pathogenesis of hepatocellular carcinoma: review and hypothesis. Hepatology 1993; 18: 669-676.
16. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997; 80: 1803-1804.
17. Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, et al. Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res 2009; 8: 4844-4850.
18. Ong ES, Zou L, Li S, Cheah PY, Eu KW, Ong CN. Metabolic profiling in colorectal cancer reveals signature metabolic shifts during tumorigenesis. Mol Cell Proteomics. 2010; Epub ahead of print
19. Ong ES, Chor CF, Zou L, Ong CN. A multi-analytical approach for metabolomic profiling of zebrafish (Danio rerio) livers. Mol Biosyst 2009; 5: 288-298.
20. Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J, et al. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res 2006; 66: 10795-10804.
21. Bylesjö M, Eriksson D, Kusano M, Moritz T, Trygg J. Data integration in plant biology: the O2PLS method for combined modeling of transcript and metabolite data. Plant J 2007; 52: 1181-1191.
22. Wu H, Xue R, Lu C, Deng C, Liu T, Zeng H, et al. Metabolomic study for diagnostic model of oesophageal cancer using gas chromatography/mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 3111-3117.
23. Wu H, Xue R, Tang Z, Deng C, Liu T, Zeng H, et al. Metabolomic investigation of gastric cancer tissue using gas chromatography/mass spectrometry. Anal Bioanal Chem 2010; 396: 1385-1395.
24. Cha D, Liu M, Zeng Z, Cheng D, Zhan G. Analysis of fatty acids in lung tissues using gas chromatography-mass spectrometry preceded by derivatization-solid-phase microextraction with a novel fiber. Anal Chim Acta 2006; 572: 47-54.
25. de Castro J, Rodríguez MC, Martínez-Zorzano VS, Llanillo M, Sánchez-Yagüe J. Platelet linoleic acid is a potential biomarker of advanced non-small cell lung cancer. Exp Mol Pathol 2009; 87: 226-233.
26. Cvetkovic Z, Vucic V, Cvetkovic B, Petrovic M, Ristic-Medic D, Tepsic J, et al. Abnormal fatty acid distribution of the serum phospholipids of patients with non-Hodgkin lymphoma. Ann Hematol 2010; 89: 775-782.
27. Menendez JA, Lupu R. Oncogenic properties of the endogenous fatty acid metabolism: molecular pathology of fatty acid synthase in cancer cells. Curr Opin Clin Nutr Metab Care 2006; 9: 346-357.
28. Ogino S, Nosho K, Meyerhardt JA, Kirkner GJ, Chan AT, Kawasaki T, et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol 2008; 26: 5713-5720.
29. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 2004; 64: 2070-2075.
30. Murata S, Yanagisawa K, Fukunaga K, Oda T, Kobayashi A, Sasaki R, et al. Fatty acid synthase inhibitor cerulenin suppresses liver metastasis of colon cancer in mice. Cancer Sci 2010; 101: 1861-1865.
31. Yu JH, Kang SG, Jung UY, Jun CH, Kim H. Effects of omega-3 fatty acids on apoptosis of human gastric epithelial cells exposed to silica-immobilized glucose oxidase. Ann N Y Acad Sci 2009; 1171: 359-364.
32. Hyde CA, Missailidis S. Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis. Int Immunopharmacol 2009; 9: 701-715.
33. Lu X, Yu H, Ma Q, Shen S, Das UN. Linoleic acid suppresses colorectal cancer cell growth by inducing oxidant stress and mitochondrial dysfunction. Lipids Health Dis 2010; 9: 106.
34. Wu WK, Cho CH, Lee CW, Fan D, Wu K, Yu J, et al. Dysregulation of cellular signaling in gastric cancer. Cancer Lett 2010; 295: 144-153.
35. Shin VY, Wu WK, Chu KM, Wong HP, Lam EK, Tai EK, et al. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer. Mol Cancer Res 2005; 3: 607-615.
36. Leung WK, To KF, Go MY, Chan KK, Chan FK, Ng EK, et al. Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma. Int J Oncol 2003; 23: 1317-1322.
37. Kuriki K, Wakai K, Matsuo K, Hiraki A, Suzuki T, Yamamura Y, et al. Gastric cancer risk and erythrocyte composition of docosahexaenoic acid with anti-inflammatory effects. Cancer Epidemiol Biomarkers Prev 2007; 16: 2406-2415.
38. Lee SE, Lim JW, Kim H. Activator protein-1 mediates docosahexaenoic acid-induced apoptosis of human gastric cancer cells. Ann N Y Acad Sci 2009; 1171: 163-169.
39. Leggett JD, Aspley S, Beckett SR, D'Antona AM, Kendall DA, Kendall DA. Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br J Pharmacol 2004; 141: 253-262.
40. Bifulco M, Di Marzo V. Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med 2002; 8: 547-550.
41. Kogan NM. Cannabinoids and cancer. Mini Rev Med Chem 2005; 5: 941-952.
42. Bisogno T, Katayama K, Melck D, Ueda N, De Petrocellis L, Yamamoto S, et al. Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells-implications for cell proliferation and differentiation. Eur J Biochem 1998; 254: 634-642.
43. Xian XS, Park H, Cho YK, Lee IS, Kim SW, Choi MG, et al. Effect of a synthetic cannabinoid agonist on the proliferation and invasion of gastric cancer cells. J Cell Biochem 2010; 110: 321-332.